Voluntary Announcement Approval Obtained for Initiating Clinical Trial for the Novel Bispecific Antibody BA1202 in China

Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech’s Dulaglutide Injection BA5101 in China

Yantai, May 15, 2023 – Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company&rsq...

Boan Biotech to Attend PEGS Boston 2023 with Its Novel ADC BA1302

Yantai, China, May 15, 2023—Boan Biotech is to present the results of its research on BA1302, a novel CD228-directed antibody drug conjugate (ADC) developed by the company, as a poster at the 19th Es...

Voluntary Announcement Patient Enrollment Completed for the Phase III Clinical Study of BA5101 in China

Boan Biotech Will Presents Results of Phase 3 Clinical Study for Denosumab Injection (BA1102) Conducted in China at the 2023 ASCO Annual Meeting

Boan Biotech recently announced that the results of phase 3 clinical study for its in-house developed Denosumab Injection (BA1102), a biosimilar product for oncology indications, will presented at the...

Supplemental Notice of Annual General Meeting

First Subject Enrolled in Boan Biotech’s International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102

Yantai, China, May 4, 2023 – Boan Biotech today announced that an international multi-center Phase 3 clinical study for its in-house developed Denosumab Injection (BA6101; BA1102) has been initi...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023

Voluntary Announcement First Subject Enrolled in International Multi-Center Phase 3 Clinical Study of Denosumab

Boan Biotech Releases Its First ESG Report, Shouldering ESG Responsibilities and Pursuing High-quality Development

Recently, Boan Biotech published its first Environmental, Social and Governance Report (“ESG Report”). Responding to internal and external stakeholders’ focuses and concerns on company develop...